Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer’s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients

Table 2 Effect of memantine on discontinuation, efficacy and safety outcomes in patients with Alzheimer’s disease

	N^a	OR	95%CI	I² (%)
All-cause discontinuation	18	0.97	0.82, 1.14	14.9
Discontinuation due to AE	14	1.18	0.91, 1.53	34.4
Discontinuation due to LoE	7	0.40	0.18, 0.87	0
	N	SMD	95%CI	I² (%)
Cognitive function	17	0.15	0.08, 0.22	24.3
Global change	10	0.16	0.08, 0.24	29.3
Neuropsychiatric symptoms	15	0.16	0.09, 0.24	27.2
Functional ability	10	0.07	−0.02, 0.15	14.7
	N	OR	95%CI	I² (%)
Proportion patients AE	6	1.05	0.88, 1.25	0
Proportion patients SAE	10	0.89	0.70, 1.13	18.3
Mortality	13	1.03	0.74, 1.44	0

AE adverse event, ChEI cholinesterase inhibitor, CI confidence interval, I² heterogeneity, LoE lack of efficacy, N number of memantine-placebo comparisons, OR odds ratio, SAE severe adverse event
^aOne study included had a factorial design

ISSN: 1471-2318